KORs are involved in depression, especially withdrawal-associated depression following the discontinuation of MOR agonists [52,53]; however, α2A-noradrenergic agonists also display efficacy in reducing opioid withdrawal symptoms [54]. The gene discussed is OPRM1; the disease is depressive disorder.